Literature DB >> 17561826

Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease.

Janneke Koerts1, Klaus L Leenders, Marthe Koning, Axel T Portman, Marije van Beilen.   

Abstract

Motor symptoms form the hallmark of Parkinson's disease (PD), although other features such as depression are often present. Currently-used depression rating scales measure affective and somatic symptoms. These somatic symptoms of depression can also be core PD symptoms, suggesting an overlap of symptoms between depression and PD. Using in vivo radiotracer methods, striatal dopaminergic dysfunction is found in both PD and depression. This study investigates to what extent the overlapping symptoms of depression and PD are associated with the striatal dopaminergic dysfunction typical of PD. Symptoms of depression were assessed in 23 PD patients who did not have major depression according to the Montgomery-Asberg depression rating scale (MADRS; cut-off < 18) and according to a trained psychologist who interviewed all patients. The striatal dopaminergic activity of patients was assessed with FDOPA-PET. Dopaminergic activity of the putamen and caudate nucleus was associated with MADRS total score and specifically with the symptom 'Concentration difficulties'. These results suggest that the typical striatal dopaminergic dysfunction of PD can cause symptoms that can also be categorized as symptoms of depression. In particular, cognitive symptoms measured with a depression rating scale may be based on the dopaminergic dysfunction of the striatum in PD patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17561826     DOI: 10.1111/j.1460-9568.2007.05580.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  16 in total

Review 1.  Pathologic correlates of dementia in individuals with Lewy body disease.

Authors:  Joshua A Sonnen; Nadia Postupna; Eric B Larson; Paul K Crane; Shannon E Rose; Kathleen S Montine; James B Leverenz; Thomas J Montine
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

Review 2.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

3.  Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism.

Authors:  Tomás R Guilarte; Neal C Burton; Jennifer L McGlothan; Tatyana Verina; Yun Zhou; Mohab Alexander; Luu Pham; Michael Griswold; Dean F Wong; Tore Syversen; Jay S Schneider
Journal:  J Neurochem       Date:  2008-09-20       Impact factor: 5.372

Review 4.  Cognitive impairment and dementia in patients with Parkinson disease.

Authors:  James B Leverenz; Joseph F Quinn; Cyrus Zabetian; Jing Zhang; Kathleen S Montine; Thomas J Montine
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

5.  Depression severity and concentration difficulties are independently associated with HRQOL in patients with unipolar depressive disorders.

Authors:  A Fattori; L Neri; A Bellomo; M Vaggi; C Mencacci
Journal:  Qual Life Res       Date:  2017-05-13       Impact factor: 4.147

6.  Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study.

Authors:  Daniela Di Giuda; Giovanni Camardese; Anna Rita Bentivoglio; Fabrizio Cocciolillo; Arianna Guidubaldi; Lorella Pucci; Isabella Bruno; Luigi Janiri; Alessandro Giordano; Alfonso Fasano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-14       Impact factor: 9.236

Review 7.  Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment.

Authors:  Stephane Thobois; Stephane Prange; Véronique Sgambato-Faure; Léon Tremblay; Emmanuel Broussolle
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-18       Impact factor: 5.081

8.  The factor structure of the Brief Symptom Inventory-18 (BSI-18) in Parkinson disease patients.

Authors:  Danielle S Abraham; Ann L Gruber-Baldini; Donna Harrington; Lisa M Shulman
Journal:  J Psychosom Res       Date:  2017-03-06       Impact factor: 3.006

9.  2-(2'-((Dimethylamino)methyl)-4'-(3-[(18)F]fluoropropoxy)-phenylthio)benzenamine for positron emission tomography imaging of serotonin transporters.

Authors:  Julie L Wang; Ajit K Parhi; Shunichi Oya; Brian Lieberman; Mei-Ping Kung; Hank F Kung
Journal:  Nucl Med Biol       Date:  2008-05       Impact factor: 2.408

10.  Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire.

Authors:  Chiara Siri; Roberto Cilia; Danilo De Gaspari; Federica Villa; Stefano Goldwurm; Catalano Marco; Gianni Pezzoli; Angelo Antonini
Journal:  Neurol Sci       Date:  2009-10-06       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.